{"id":"NCT00413010","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).","officialTitle":"An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-02","completion":"2008-03","firstPosted":"2006-12-19","resultsPosted":"2009-12-02","lastUpdate":"2021-02-10"},"enrollment":356,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":["Lyrica"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Arm 2","type":"PLACEBO_COMPARATOR"},{"label":"Arm 1","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from baseline observed following 8 weeks of double-blind treatment or at earlier termination during the double-blind treatment phase and analyzed using a mixed linear model for repeated measures.","primaryOutcome":{"measure":"Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores","timeFrame":"Baseline, 8 weeks","effectByArm":[{"arm":"Pregabalin","deltaMin":-7.6,"sd":0.35},{"arm":"Placebo","deltaMin":-6.4,"sd":0.36}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":68,"countries":["United States","Czechia","Estonia","Finland","Hungary","Russia","Serbia","Ukraine"]},"refs":{"pmids":["22302014"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Dizziness","Headache","Nausea","Somnolence","Diarrhea"]}}